Journal Content Recommendation
01
Exploring the “Urban Advantage” in Access to Immunization Services: A Comparison of Zero-Dose Prevalence Between Rural, and Poor and Non-poor Urban Households Across 97 Low- and Middle-Income Countries
The study used data from nationally representative household surveys of 97 LMICs to investigate 201,283 children aged 12–23 months and compare the prevalence of zero-dose children in poor and non-poor urban and rural areas of low- and middle-income countries (LMICs). The pooled prevalence of zero-dose children was 6.5% among the urban non-poor, 12.6% for the urban poor, and 14.7% for the rural areas. There were significant differences between these areas in 43 countries.
https://doi.org/10.1007/s11524-024-00859-7
02
Effect of an HPV Vaccination Multi-Level, Multi-Component Program on HPV Vaccination Initiation and Completion in a Pediatric Clinic Network
Interventions targeting multi-level determinants of vaccination behavior are crucial for improving HPV vaccination rates. The study aimed to implement and evaluate the adapted Adolescent Vaccination Program (AVP), a clinic-based, multi-level, multi-component intervention to increase HPV vaccine initiation and completion rates in a five-clinic pediatric network in Bexar County, Texas.
The findings indicated that the AVP improved HPV vaccination initiation and completion rates in clinic settings and that AVP strategies facilitated resilience during the pandemic.
https://doi.org/10.3390/vaccines12050510
03
Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions
As of December 31, 2022, 71.0% and 71.3% of children born in 2016 and 2017, respectively, were up to date on their routine vaccinations by two years of age compared to 69.1%, 64.7%, and 60.6% for children born in 2018, 2019, and 2020, respectively. There was a slight but steady decrease in vaccination coverage prior to the pandemic, but the percentage of children up to date on routine vaccinations declined markedly during the COVID-19 pandemic.
https://doi.org/10.1016/j.vaccine.2024.05.045
04
Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence
This study reports the results of a systematic review of the cost-effectiveness of aQIV among older persons (those aged 65 and over) with weaker immune systems. 10 full-text papers included were modeling studies and exhibited heterogeneity in approach, perspective, and parameter estimation. There is a broad consensus on the cost-effectiveness of aQIV in this population group.
https://doi.org/10.3390/vaccines12050523
Global/National Policy Updates
05
WHO：Considerations for human papillomavirus (HPV) vaccine product choice
The latest published document summarizes current technical and programmatic information on WHO-prequalified human papillomavirus (HPV) vaccine products in order to facilitate informed country choices for HPV vaccine introduction (or product switch within immunization programmes).
https://www.who.int/publications/i/item/9789240089167
06
China unveils national disease control action plan for 2024-25
China has released a comprehensive national disease prevention and control action plan for 2024-25, detailing 10 specific measures to enhance the country’s public health system. The plan, jointly issued by the National Disease Control and Prevention Administration and nine other departments, outlines actions to prevent and control acute respiratory infectious diseases, including COVID-19 and other major infectious diseases. The plan aims to establish a modern disease control and prevention system by 2025 characterized by rapid response, efficient infectious disease monitoring, early warning, and an emergency response system.
http://english.scio.gov.cn/m/pressroom/2024-05/30/content_117224112.htm
